Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
April 28 — Senate Finance Committee Republicans April 28 called on the CMS to pull a Medicare Part B proposed drug payment rule that the lawmakers said in a letter would disrupt care for vulnerable patients.
Democrats on the Finance Committee also took issue with the proposal in an April 27 letter. However, they didn't go as far as to call for the CMS to pull the rule.
The lawmakers' letters represent the latest in a string of concerns expressed over the proposed rule, which covers Part B drugs, such as cancer medications, that are administered in a doctor's office or hospital outpatient department.
The proposed payment model (81 Fed. Reg. 13,229), released March 11 (46 HCDR, 3/9/16), would test new ways to support physicians and other clinicians “as they choose the drug that is right for their patients,” the Centers for Medicare & Medicaid Services said at the time.
In their letter to the agency, Finance ranking member Ron Wyden (D-Ore.) and other Democrats on the committee asked the CMS to work with affected parties before going forward with a final rule.
Patients, providers and other stakeholders have raised numerous concerns about the model's potential to have unintended consequences on Medicare beneficiaries' access to care and to physician-administered drugs, Wyden and his Democratic committee colleagues said.
Furthermore, the proposed payment model would require health-care providers across the nation to engage in drastic changes in payment procedures, Finance Chairman Orrin Hatch (R-Utah) and other committee Republicans told the CMS in their letter.
For example, a proposed average sales price (ASP) payment reduction in the rule would harm access to “vital drugs” because many providers would face prescription costs that exceed the new Medicare payment amount offered under the model, the Republican lawmakers said.
This problem would be especially acute for small physician practices and practices in rural areas, Hatch and his colleagues said. Doctors who have trouble accessing drugs with the reduced ASP payment would likely refer patients to hospital outpatient departments, which are a less-convenient and more costly setting, they added.
Overall, the ASP proposal would limit beneficiaries' choice, increase costs and could further hospital acquisitions of physician practices, the Republicans said.
The letter from Finance Democrats also outlined concerns about reducing ASP and how doing so would affect drug access and push beneficiaries to more costly hospital outpatient department.
A group representing community oncology practices, the Community Oncology Alliance, praised the letters.
“It is encouraging to see that Congress is beginning to see what a disaster the Medicare Part B experiment will be for seniors and their providers,” Ted Okon, the group's executive director, said in an April 28 statement provided to Bloomberg BNA.
The recent letters from both the Republican and Democratic members on the Finance Committee “leave us hopeful that this misguided proposal will be rejected outright,” Okon said. Nothing short of a full withdrawal would be enough, he said.
Okon also called the proposed rule a “dangerous experiment” because beneficiaries couldn't opt out of the model.
A drug industry group also applauded efforts to quash the rule.
The Pharmaceutical Research and Manufacturers of America (PhRMA) is strongly opposed to the proposed Medicare Part B payment changes, and it supports withdrawing the proposal, Allyson Funk, a spokeswoman for the association, told Bloomberg BNA April 28.
“[W]e expressed grave concern about the consequences of this proposal” and joined with more than 300 other patient and provider groups to express displeasure with this rule, Funk said.
Shortly after the CMS published the rule, 317 regional and national medical groups, including PhRMA, asked Congress to prevail upon the CMS to permanently withdraw the proposal (54 HCDR, 3/21/16).
Comments (CMS-1670-P) on the rule are due May 9.
To contact the reporter on this story: Michael D. Williamson in Washington at email@example.com
To contact the editor responsible for this story: Brent Bierman at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)